Posted by Michael Wonder on 26 Jul 2022
LFB announces the approval of Cevenfacta (eptacog beta) in the European Union
25 July 2022 - The first new bypassing agent approved in the European Union for the treatment and control of bleeding episodes in haemophilia A and B patients with inhibitors in over 2 decades.
LFB today announced that the EMA has granted on 15 July a Marketing Authorisation for Cevenfacta (eptacog beta), as the first new bypassing agent in over 20 years.
